SL
SLGL.US Sol Gel Technologies Ltd
- Market cap
- USD 173M
- P/E
- -
- P/B
- 4.23x
- ROE
- -40.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is SLGL.US undervalued?
Graham numberThe Graham number of Sol Gel Technologies Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Sol Gel Technologies Ltd fundamental analysis
No fundamental analysis for Sol Gel Technologies Ltd yet.
Sol Gel Technologies Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Sol Gel Technologies Ltd
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in…
Full company profileSol Gel Technologies Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Sol Gel Technologies Ltd annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 174K | 129K | 22.9M | 8.77M | 31.3M | 3.88M | 1.55M | 11.5M | 19.4M | 987K |
| Gross Profit | -359K | -126K | -28.0M | -17.7M | 8.77M | 10.9M | -8.80M | 1.55M | 11.5M | 19.4M | - |
| Operating Income | -20.8M | -31.6M | -33.5M | 26.0M | -30.2M | 2.96M | -16.2M | -29.3M | -12.0M | -7.54M | -18.8M |
| EBITDA | -20.4M | -31.2M | -32.8M | -25.1M | -29.3M | 3.84M | -15.7M | -29.0M | -11.8M | -7.43M | -18.8M |
| Net Income | -20.8M | -31.6M | -32.2M | -24.6M | -27.4M | 3.22M | -14.9M | -27.2M | -10.6M | -6.13M | -17.4M |
| EPS | -1.77 | -1.76 | -1.80 | -1.26 | -1.21 | 0.14 | -0.65 | -10 | -3.80 | -2.20 | -5.30 |
| Balance Sheet | |||||||||||
| Total Assets | 11.0M | 15.3M | 69.7M | 61.3M | 59.2M | 69.2M | 46.6M | 45.3M | 35.8M | 29.9M | 50.2M |
| Total Liabilities | 42.3M | 68.0M | 5.77M | 8.84M | 8.31M | 13.6M | 4.42M | 6.64M | 7.00M | 7.11M | 7.39M |
| Shareholders' Equity | -31.3M | -52.7M | 63.9M | 52.5M | 50.8M | 55.6M | 42.2M | 38.6M | 28.9M | 22.8M | 42.8M |
| Cash & Short-term Investments | 7.00M | 9.02M | 63.0M | 50.4M | 50.2M | 43.2M | 33.6M | 38.0M | 23.9M | 24.0M | 44.4M |
| Total Debt | 37.3M | 65.3M | - | 2.05M | 1.97M | 1.59M | 772K | 1.65M | 1.31M | 991K | 805K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -18.5M | -24.1M | -23.5M | -22.5M | -25.2M | -7.69M | -9.48M | -17.7M | -13.9M | 322K | - |
| Capital Expenditure | 385K | 1.93M | 1.05M | 597K | 449K | 143K | 171K | 134K | 2.00K | 47.0K | 0.00 |
| Free Cash Flow | -18.9M | -26.0M | -24.5M | -23.1M | -25.7M | -7.83M | -9.66M | -17.9M | -13.9M | 275K | - |
| Ratios | |||||||||||
| ROE | - | - | -50.4% | -46.9% | -53.9% | 5.8% | -35.4% | -70.5% | -36.7% | -26.9% | -40.6% |
| ROA | -189.1% | -206.1% | -46.2% | -40.1% | -46.3% | 4.7% | -32.0% | -60.1% | -29.5% | -20.5% | -34.6% |
| Net Profit Margin | - | -18,142.5% | -24,963.6% | -107.4% | -312.4% | 10.3% | -384.3% | -1,752.8% | -91.7% | -31.6% | -1,760.8% |
| Debt to Equity | - | - | - | 0.04x | 0.04x | 0.03x | 0.02x | 0.04x | 0.05x | 0.04x | 0.02x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Sol Gel Technologies Ltd dividends
Sol Gel Technologies Ltd has not paid dividends in the last 9 fiscal years.
Last stock split: 1:10 on May 5, 2025.
Who owns Sol Gel Technologies Ltd
- Insiders 59.73%
- Institutions 40.27%
- Public & others 0.00%
- Shares outstanding 3.27M
- Free float 353K
Top funds holding SLGL.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| ARK Israel Innovative Technology ETF | 30.0K | 0.92% | 0.00% | Oct 2026 |
| Mandarine Global Microcap G EUR | 2.70K | 0.08% | -10.00% | Jul 2026 |
| Invesco NASDAQ Future Gen 200 ETF | 1.70K | 0.05% | +1.91% | Oct 2026 |
| Fidelity Nasdaq Composite Index | 680.00 | 0.02% | -66.91% | Aug 2026 |
Top institutions holding SLGL.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Opaleye Management Inc | 500K | 15.27% | 0.00% | Jun 2026 |
| Great Point Partners LLC | 274K | 8.38% | 0.00% | Jun 2026 |
| Phoenix Financial Ltd | 146K | 4.46% | -30.69% | Jun 2026 |
| Trails Edge Capital Partners, LP | 139K | 4.26% | +63.10% | Jun 2026 |
| Affinity Asset Advisors, LLC | 84.9K | 2.59% | +142.57% | Jun 2026 |
| Squadron Capital Management LLC | 52.0K | 1.59% | +67.74% | Jun 2026 |
| Citadel Advisors Llc | 32.6K | 0.99% | -12.35% | Jun 2026 |
| Gilder Gagnon Howe & CO LLC | 22.5K | 0.69% | 0.00% | Jun 2026 |
| Stonepine Capital Management Llc | 14.5K | 0.44% | -47.91% | Jun 2026 |
| Yelin Lapidot Holdings Management Ltd | 10.4K | 0.32% | -41.51% | Jun 2026 |
| Jane Street Group LLC | 8.36K | 0.26% | +16.85% | Jun 2026 |
| MENORA MIVTACHIM HOLDINGS LIMITED | 7.61K | 0.23% | 0.00% | Jun 2026 |
| HRT FINANCIAL LLC | 6.26K | 0.19% | +94.59% | Jun 2026 |
| Navellier & Associates Inc | 5.79K | 0.18% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 4.61K | 0.14% | -10.91% | Jun 2026 |
| LPL Financial Corp | 3.90K | 0.12% | +12.54% | Jun 2026 |
| Millennium Management LLC | 3.34K | 0.10% | 0.00% | Jun 2026 |
| XTX Topco Ltd | 2.97K | 0.09% | -62.87% | Jun 2026 |
| TWO SIGMA SECURITIES, LLC | 2.71K | 0.08% | 0.00% | Jun 2026 |
| BlackRock Inc | 953.00 | 0.03% | 0.00% | Jun 2026 |
Sol Gel Technologies Ltd company profile
- Company name
- Sol Gel Technologies Ltd
- Ticker
- SLGL.US
- ISIN
- IL0011417206
- Exchange
- USA Stocks
- Listed since
- Jan 23, 2018
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 28
- Fiscal year end
- December
- Address
- 7 Golda Meir Street, Ness Ziona, Israel, 7403650
- Phone
- 972 8 931 3433
- Website
- sol-gel.com
About Sol Gel Technologies Ltd
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat olmsted syndrome. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
Sol Gel Technologies Ltd management
5- Mr. Eyal Ben-OrChief Financial Officer · born 1984
- Dr. Itzik YosefChief Operating Officer · born 1976
- Mr. Michael GlezinChief Business Officer · born 1983
- Dr. Ofer ToledanoVice President of Research & Development · born 1965
- Mr. Moshe ArkinCEO & Executive Chairman · born 1953